Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences

  title={Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences},
  author={Antoni Sicras-Mainar and Ruth Navarro-Artieda and M. Blanca-tamayo and Victoria Gimeno-de la Fuente and Jordi Salvatella-Pasant},
  journal={Current Medical Research and Opinion},
  pages={2757 - 2764}
Abstract Study objective: Population based study to determine the clinical consequences and economic impact of using escitalopram (ESC) vs. citalopram (CIT) and venlafaxine (VEN) in patients who initiate treatment for a new episode of major depression (MD) in real life conditions of outpatient practice. Methods: Observational, multicenter, retrospective study conducted using computerized medical records (administrative databases) of patients treated in six primary care centers and two hospitals… Expand
Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study
It is indicated that a combination with paliperidone is significantly better than monotherapy with citalopram whether synergistic or add-on for patients with SDs. Expand
Efficacy of escitalopram monotherapy in the treatment of major depressive disorder
Escitalopram monotherapy is effective and safe in the treatment of major depressive disorder in Chinese patients, and therapeutic efficacy is dependent on the severity of MDD. Expand
Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting.
Based on the findings from this cost-effectiveness analysis, the favorable clinical benefit of escitalopram resulted in a positive health economic benefit in the Netherlands. Expand
The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants.
It is suggested that short-term use of BZDs does not impair cognitive function of MDD patients; conversely, it could improve the information processing speed after acute treatment and at 1 year follow up. Expand
Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis
Unlike the analyses of diabetes and obesity management, no significant differences in the proportion of depression-free days or health service costs were found between the alternative levels of practice nurse involvement. Expand
Suggesting a Way to Understand the Actual Potential of Anti-Alzheimer’s Disease Drugs That Show Promise in Transgenic Mouse Models
This commentary focuses on small drugs with the same chemical formula, but with different 3-D structure, which a significant number of drugs approved for human consumption for fairly different illnesses have a special structural characteristic called stereoisomerism. Expand


Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.
Geriatric patients treated with escitalopram had better treatment persistence, fewer hospitalizations, and lower medical and total healthcare costs than patientstreated with citaloprams. Expand
Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder
It is demonstrated that escitalopram is a cost-effective first-line treatment option for major depressive disorder and is associated with lower healthcare costs. Expand
Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK
The results of this real-life study bring additional evidence of escitalopram appearing to be a cost-effective treatment for patients suffering from severe depression as diagnosed in routine practice and could be considered for first-line treatment in these patients. Expand
Comorbilidad y coste ambulatorio asociado a los pacientes con trastornos depresivos en un ámbito poblacional
Prevalence of DD was higher, particularly in women, and following adjustment in accordance with comorbidity, age and sex, DD outpatients used more health care resources and implied higher costs. Expand
Escitalopram versus other antidepressive agents for depression.
Some statistically significant differences favouring escITALopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxettine). Expand
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder
A double-blind, randomized clinical trial was performed in which general practitioners and psychiatrists compared fixed doses of escitalopram with citaloprams over 8 weeks in outpatients with major depressive disorder (MDD) and confirmed that escITALopram has a superior effect in MDD. Expand
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Patterns of antidepressant drug use and depression-related and all-cause medical costs for patients who switched therapy between 2 drug classes, selective serotonin reuptake inhibitors (SSRIs) and the selective norepinephrine reptake inhibitor (SNRI) venlafaxine are explored. Expand
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression
Venlafaxine appears more effective than SSRIs, and at least as effective as tricyclic antidepressants, in the treatment of major depressive episode. Expand
Clinical validity of a population database definition of remission in patients with major depression
Results show an acceptable level of concordance between remission obtained from the computerized databases and clinical criteria, and the major discrepancies were found in diagnostic accuracy. Expand
[Prevalence of mental disorders and associated factors: results from the ESEMeD-Spain study].
The ESEMeD-Spain study can provide careful outcomes to understand the impact of mental disorders in Spain; the influence of sociodemographic factors on its presence and age of onset of the disorders. Expand